Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 765 across all filing types
Latest filing 2026-05-14 Director's Dealing
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
Final Director's Interest Notice 3 pages 319.2KB
Director's Dealing Classification · 87% confidence The document is an ASX Appendix 3Z "Final Director’s Interest Notice" disclosing the personal shareholdings and relevant interests of a retiring director under Listing Rule 3.19A.3. This is a report of a director’s personal share transactions and holdings (insider interests), which falls under the “Director's Dealing” category.
2026-05-14 English
Quarterly Activities/Appendix 4C Cash Flow Report 8 pages 455.2KB
Regulatory Filings
2026-04-28 English
Director Retirement 1 page 137.7KB
Board/Management Information Classification · 100% confidence The document is a formal announcement from Biotron Limited regarding the retirement of their long-term Chairman and the appointment of a new Chairman. It is a clear notification of changes in the company's board of directors. There is no financial data, report, or presentation included. The content fits the category of Board/Management Information, which covers announcements of changes in the company's board or senior management.
2026-04-09 English
Director Appointment Graeme Wald & Appendix 3X 3 pages 304.5KB
Board/Management Information Classification · 95% confidence The document is an announcement from Biotron Limited regarding the appointment of a new Non-Executive Director, Graeme Wald. It includes biographical details, the effective date of appointment, and references compliance with Listing Rule 3.19A. The document also includes an Appendix 3X, which is an Initial Director's Interest Notice, disclosing the director's relevant interests in securities. There is no financial data, earnings information, or report content. The document is clearly about a change in the company's board of directors. Therefore, it fits the category of Board/Management Information (MANG). The document length is 4712 characters, which is sufficient for a detailed announcement but not a full report. Hence, the classification is MANG with high confidence.
2026-03-29 English
Investor Update 20 pages 2.3MB
Investor Presentation Classification · 95% confidence The document is titled 'INVESTOR UPDATE ASX:BIT | March 2026' and contains detailed information about the company's drug portfolio, clinical trial progress, regulatory pathways, market opportunities, and financial summary. It is structured as a presentation with forward-looking statements, pipeline descriptions, regulatory updates, and milestones. There are no full financial statements or comprehensive financial performance data typical of annual or interim reports. The document is lengthy (15,000 characters) and appears to be a detailed investor presentation focusing on strategy, product development, and market positioning rather than a formal report or regulatory filing. Therefore, the most appropriate classification is 'Investor Presentation (IP)'.
2026-03-18 English
Hepatitis B Virus Program Update 2 pages 221.2KB
Regulatory Filings Classification · 95% confidence The document is a short announcement (3964 characters) from Biotron Limited providing an update on their Hepatitis B Virus program, including new data on their drug candidate BIT-HBV001 and an update on the acquisition and integration of Sedarex Limited. It also mentions an upcoming investor webinar. The document does not contain detailed financial statements, comprehensive financial analysis, or regulatory filings such as annual or quarterly reports. It is primarily an operational and program update with some corporate news. The length and content indicate it is not a full report but rather a regulatory announcement or update. Given the nature of the content and the absence of financial data or detailed report structure, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2026-03-17 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.